Evidence map›Paper›PMID 37023030›Full record

SynthesisPloS one2023

Peripheral nervous system involvement associated with COVID-19. A systematic review of literature.

Andreea-Raluca Hanganu, Alexandru Constantin, Elena-Sonia Moise, Cristian-Mihail Niculae, Ioana Diana Olaru, Cristian Băicuș, Adriana Hristea

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Andreea-Raluca HanganuDepartament of Infectious Diseasese, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.ORCID 0000-0001-8787-5018
Alexandru ConstantinColentina Clinical Hospital, Internal Medicine Department, Bucharest, Romania.
Elena-Sonia MoiseDepartment of Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Cristian-Mihail NiculaeDepartament of Infectious Diseasese, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Ioana Diana OlaruLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Cristian BăicușDepartament of Infectious Diseasese, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.ORCID 0000-0002-7954-0098
Adriana HristeaDepartament of Infectious Diseasese, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROLondon School of Hygiene & Tropical Medicine · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is increasing evidence of both central and peripheral nervous system (PNS) involvement in COVID-19. We conducted this systematic literature review to investigate the characteristics, management and outcomes of patients with PNS, including the types and severity of cranial nerves (CN) involvement. We systematically searched on PubMed for studies reporting adult patients diagnosed with COVID-19 and PNS involvement until July 2021. From 1670 records, 225 articles matched the inclusion criteria, with a total of 1320 neurological events, in 1004 patients. There were 805 (61%) CN, 350 (26.5%) PNS, and 165 (12.5%) PNS plus CN events. The most frequently involved CN were the facial, vestibulo-cochlear and olfactory nerve in 27.3%, 25.4% and 16.1%, respectively. Guillain-Barre syndrome spectrum was identified in 84.2% of PNS events. We analysed 328 patients reported in 225 articles with CN, PNS, and PNS plus CN involvement. The patients with CN involvement were younger (mean age 46.2±17.1, p = .003), and were more frequently treated as outpatients (p < .001), mostly with glucocorticoids (p < .001). Patients that had PNS with or without CN involvement were more likely to be hospitalized (p < .001), and to receive intravenous immunoglobulins (p = .002) or plasma exchange (p = .002). Patients with CN, PNS, and PNS plus CN had severe COVID -19 disease in 24.8%, 37.3%, 34.9% respectively. The most common neurological outcome was mild/moderate sequelae in patients with CN, PNS, and PNS plus CN in 54.7%, 67.5% and 67.8% respectively (p = .1) and no significant difference was found between the three categories regarding death, disease severity, time from disease onset to neurological symptoms, lack of improvement and complete recovery. CN involvement was the most frequent PNS finding. All three categories of PNS involvement were rather associated to non-severe COVID-19 but it may be an important cause of hospitalization and post COVID-19 sequelae.

Indexed as

COVID-19Guillain-Barre SyndromeAdultHumansImmunoglobulins, IntravenousMiddle AgedPeripheral Nervous SystemPlasma ExchangeImmunoglobulins, Intravenous

Identifiers

PMID37023030
PMCPMC10079054
OpenAlexW4362658197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.